Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR. iDose TR is a micro-invasive intraocular implant that has been created to continuously provide therapeutic levels of a proprietary formulation of travoprost.

Glaukos announced positive results for a prospective, multicenter clinical trial designed to assess the safety of the surgical exchange procedure for iDose TR (travoprost intraocular implant) in subjects who had previously received an iDose TR.